| 摘要 |
The present invention provides a kit or an integrated system for providing a prognosis of a subject having a lung cancer comprising reagents that specifically bind to at least two biomarkers selected from a group consisting of: rnd3, wnt3a, erbb3, lck, sh3bgr, fut3, il11, cdc6, cdk2apl, bagl, emx2, six3, and brca1; and a label for detecting expression levels of the biomarkers. |
